01 10Ilaris
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 873
2019 Revenue in Millions : 671
Growth (%) : 30
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 1,059
2020 Revenue in Millions : 873
Growth (%) : 21
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 1,133
2021 Revenue in Millions : 1,059
Growth (%) : 7
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 1,355
2022 Revenue in Millions : 1,133
Growth (%) : 20
Main Therapeutic Indication : Rare Disease
Currency : USD
2014 Revenue in Millions : 67.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Rare Disease
Currency : USD
2015 Revenue in Millions : 199
2014 Revenue in Millions : 236
Growth (%) : 19%
Main Therapeutic Indication : Rare Diseases
Currency : USD
2016 Revenue in Millions : 283
2015 Revenue in Millions : 236
Growth (%) : 20
Main Therapeutic Indication : Rare Diseases
Currency : USD
2017 Revenue in Millions : 402
2016 Revenue in Millions : 283
Growth (%) : 42
Main Therapeutic Indication : Rare Diseases
Currency : USD
2018 Revenue in Millions : 554
2017 Revenue in Millions : 402
Growth (%) : 38%
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 671
2018 Revenue in Millions : 554
Growth (%) : 21
